AI Governance in Healthcare: A Buyer Guide
AI governance in healthcare is a working control system, not a policy document. Buyers should define the intended use, evidence standard, human decision point, data responsibilities, monitoring plan, and owner before approving a tool.
What does AI governance mean in healthcare?
AI governance is the set of decisions, controls, and review steps that keep an AI system within its intended purpose. In healthcare, that purpose may involve clinical support, administration, operations, research, or patient communication. Each use carries a different risk profile and should not be approved as if it were the same product.
The NIST AI Risk Management Framework is useful because it treats risk management as a continuous activity across design, deployment, and use. A healthcare buyer can adapt that structure without pretending that a framework is a substitute for clinical, legal, privacy, or security review.
The first governance question is simple: what decision is the system helping someone make? If the answer is vague, the procurement process is not ready. A clear decision makes the evidence, user training, escalation route, and monitoring requirements easier to specify.
Rule: approve a defined use case, not an impressive demonstration.
Which risks should a buyer assess first?
Start with five risk areas. They are broad enough for early screening and specific enough to produce a useful procurement record.
Do not score risk only from the vendor questionnaire. Test the proposed system against the workflow in which it will actually be used, including incomplete data, unusual cases, handoffs, and the points where a user may accept an answer too quickly.
- Clinical or operational harm: what happens if the output is wrong, late, missing, or misunderstood?
- Data handling: which data enters the system, where it is processed, and how long it is retained?
- Human oversight: who reviews the output and what can they do when it is not credible?
- Security and access: which identities, devices, integrations, and logs are involved?
- Equity and usability: could performance or access differ across the people and settings the service must support?
How should evidence match the use case?
Evidence should match the claim. A tool that drafts administrative text needs a different test from a tool that prioritises clinical work. Buyers should ask for the evaluation design, the population or workflow tested, the limits of the result, and the conditions under which the result may not transfer.
A product demo proves that a workflow can be shown. It does not prove that the workflow is safe, reliable, or valuable in normal operations. Ask to see failure examples and the steps taken when the system is uncertain.
For software that may influence a medical device function, review the FDA overview of software as a medical device alongside the organisation’s own regulatory advice. The point is not to assign a classification in a sales call. The point is to identify when specialist review is required.
| Evidence question | Why it matters | Buyer record |
|---|---|---|
| What was tested? | Defines the boundary of the result. | Use case, workflow, users, and data conditions. |
| What failed? | Shows whether limitations are understood. | Known failure modes and mitigations. |
| Who reviewed it? | Separates technical testing from domain judgement. | Names, roles, and decision rights. |
| What changes after launch? | Makes monitoring part of the purchase. | Metrics, thresholds, review dates, and owner. |
What should be in the governance file?
A governance file should be short enough to use and detailed enough to audit. It should follow the product from approval to retirement. Store the version being evaluated, the intended use, the excluded uses, the data map, the evidence summary, and the decision log in one controlled location.
Include a plain-language user notice. People need to know when AI is involved, what the output means, and when a human must review it. Training should use realistic examples, including a wrong answer that looks plausible.
Assign owners by responsibility rather than by department name. A clinical owner, product owner, security owner, privacy owner, and operations owner may be different people. The buyer should know who can pause the system and who can approve a change.
- Purpose and scope: approved task, users, setting, and exclusions.
- Evidence and limits: evaluation method, result, known gaps, and decision boundary.
- Data and security: inputs, access, retention, vendors, integrations, and logs.
- Operations: training, escalation, support, incident response, and change control.
- Review: monitoring measures, review cadence, pause criteria, and retirement plan.
AI governance models compared
The right model depends on the consequence of the decision, the number of workflows, and the organisation’s ability to monitor use. A small controlled pilot can be more responsible than a broad rollout with no owner.
The model should also reflect the supplier relationship. A hosted product, a configurable platform, and a custom system create different responsibilities for data, updates, logs, and incident response.
| Model | Best fit | Strength | Main weakness |
|---|---|---|---|
| Central review board | Several high-impact use cases | Consistent decisions and records | Can become slow without risk tiers |
| Risk-tiered approval | Mixed portfolio of uses | Matches review effort to consequence | Needs clear scoring rules |
| Embedded workflow owner | One defined operational process | Fast feedback from actual users | May miss enterprise-wide controls |
| Pilot with gate | Material uncertainty before scale | Limits commitment while evidence grows | Weak if success criteria are vague |
How can a buyer test governance before rollout?
Run a limited test with a named workflow, a fixed user group, and a written stop rule. Capture the input, output, reviewer action, time taken, and exception. Do not ask users only whether they liked the tool. Ask whether it changed the work in the intended way and whether it introduced a new risk.
Review the results with the people who will carry the risk after launch. A security team can assess access controls. A clinical or operational team can assess workflow and harm. A procurement team can assess contractual duties. Governance works when those views meet in one decision record.
Before scale, confirm that monitoring is possible with the available logs and data. If the organisation cannot see use, errors, overrides, or access, it cannot manage the system responsibly.
- Write the use case and excluded uses in one page.
- Set evidence, security, privacy, and human-review requirements.
- Test normal, edge, and failure cases with representative users.
- Record exceptions, owners, and the decision to continue, change, pause, or stop.
- Set a review date before the first production user starts.
What does not matter as much as buyers think?
A large feature list does not prove that a system fits the workflow. A polished interface does not show how exceptions are handled. A benchmark score does not answer whether the tool is appropriate for a specific population, process, or decision.
The useful question is not whether a vendor uses the word responsible. It is whether the buyer can inspect the claim, reproduce the test where appropriate, assign a person to each control, and act when the result falls outside the intended boundary.
One-page buyer worksheet
Use this worksheet before approval. Write the intended use, excluded uses, users, decision affected, evidence needed, human review point, data boundary, and owner. Then write the conditions that would pause the tool.
Keep the worksheet with the research brief, procurement record, or operating review. It turns a broad market question into a set of checks that can be answered, assigned, and revisited when new evidence arrives.
- Claim being made and evidence that supports it
- Known failure or misuse case and safe response
- Privacy, security, and access review owner
- Monitoring measure, threshold, and review date
- Change, incident, and retirement decision path
FAQ
Is an AI policy enough for healthcare governance?
No. A policy sets direction. Governance also needs a defined use case, evidence, owners, monitoring, training, and a route to pause or change the system.
Who should own an AI approval?
The owner should be the person accountable for the workflow and its outcome, supported by privacy, security, legal, technical, and clinical or operational reviewers as needed.
What evidence should a vendor provide?
Ask for the evaluation design, tested conditions, failure cases, limitations, update process, and evidence that matches the specific claim being made.
Should every AI use go to the same review board?
Not always. Risk tiers can keep low-consequence uses moving while reserving deeper review for tools that influence health, safety, access, or sensitive decisions.
When should a buyer stop a pilot?
Stop when a defined safety, privacy, security, reliability, or workflow threshold is breached, or when the organisation cannot monitor the system well enough to make a sound decision.
Bottom line
Need an evidence-led view of an AI market or buyer landscape? Review the enterprise AI software report or request a focused research brief.